SG11201407425SA - Methods for inhibition of shc-1/p66 to combat aging-related diseases - Google Patents

Methods for inhibition of shc-1/p66 to combat aging-related diseases

Info

Publication number
SG11201407425SA
SG11201407425SA SG11201407425SA SG11201407425SA SG11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA
Authority
SG
Singapore
Prior art keywords
international
taiwan
shc
dist
east
Prior art date
Application number
SG11201407425SA
Inventor
Shau-Feng Chang
Chun-Hsien Ma
Kuo-Yi Yang
Original Assignee
Ind Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Tech Res Inst filed Critical Ind Tech Res Inst
Publication of SG11201407425SA publication Critical patent/SG11201407425SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 July 2014 (03.07.2014) WIPOIPCT (10) International Publication Number WO 2014/101366 A1 (51) International Patent Classification: A61K31/353 (2006.01) A61P 39/06 (2006.01) A61P 3/10 (2006.01) A61P 43/00 (2006.01) (21) International Application Number: (22) International Filing Date: PCT/CN2013/075599 14 May 2013 (14.05.2013) (25) Filing Language: (26) Publication Language: (30) Priority Data: 13/727,387 26 December 2012 (26.12.2012) English (71) Applicant: INDUSTRIAL TECHNOLOGY RE­ SEARCH INSTITUTE [CN/CN]; No. 195, Sec.4, Chung Hsing Rd., Chutung, Hsinchu, Taiwan 31040 (CN). AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. US (72) Inventors: CHANG, Shau-Feng; 2F„ No. 43, Lane 42, Dongguang Rd., East Dist., Hsinchu City 30069, Taiwan (CN). MA, Chun-Hsien; 4F„ No. 32, Ln. 1050, Minghu Rd., East Dist., Hsinchu City 300, Taiwan (CN). YANG, Kuo-Yi; No. 383, Sec. 2, Guangfu Rd., East Dist., Hsinchu City 300, Taiwan (CN). (74) Agent: LIU, SHEN & ASSOCIATES; A0601, Huibin Building, No. 8 Beichen Dong Street, Chaoyang District, Beijing 100101 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, English (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) V © o CJ (54) Title: METHODS FOR INHIBITION OF SHC-1/P66 TO COMBAT AGING-RELATED DISEASES (57) Abstract: The present invention relates to methods of treating one or more symptoms of SHC- a l/p66-related disease, inhibit - ing ROS generation or for the manufacture of a medicament in the above-mentioned treatment.
SG11201407425SA 2012-12-26 2013-05-14 Methods for inhibition of shc-1/p66 to combat aging-related diseases SG11201407425SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/727,387 US20140179774A1 (en) 2012-12-26 2012-12-26 Methods for inhibition of shc-1/p66 to combat aging-related diseases
PCT/CN2013/075599 WO2014101366A1 (en) 2012-12-26 2013-05-14 Methods for inhibition of shc-1/p66 to combat aging-related diseases

Publications (1)

Publication Number Publication Date
SG11201407425SA true SG11201407425SA (en) 2014-12-30

Family

ID=50975338

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407425SA SG11201407425SA (en) 2012-12-26 2013-05-14 Methods for inhibition of shc-1/p66 to combat aging-related diseases

Country Status (8)

Country Link
US (1) US20140179774A1 (en)
EP (1) EP2838528A4 (en)
JP (1) JP6305422B2 (en)
KR (2) KR20150013629A (en)
CN (1) CN104487069A (en)
IN (1) IN2014MN02382A (en)
SG (1) SG11201407425SA (en)
WO (1) WO2014101366A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026441A1 (en) * 2016-08-01 2018-02-08 The Regents Of The University Of California Methods for preventing or treating fibrotic diseases
CA3139336A1 (en) 2019-05-30 2020-12-03 Becton, Dickinson And Company Cartridge adapter for drug delivery device
KR20230083169A (en) 2021-12-02 2023-06-09 대주전자재료 주식회사 Porous silicon-carbon composite, preparation method thereof, and negative electrode active material comprising same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023210A1 (en) * 1995-12-26 1997-07-03 Suntory Limited Antiobestic agent containing procyanidin as the active ingredient
JPH09291039A (en) * 1995-12-26 1997-11-11 Suntory Ltd Antiobestic medicine comprising procyanidin as active ingredient
GB9906515D0 (en) * 1999-03-22 1999-05-19 Europ I Of Oncology Materials and methods relating to the effects oF P66 expression
AU6648200A (en) 1999-06-18 2001-01-09 Dry Creek Nutrition, Inc. Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
KR100509119B1 (en) 1999-07-16 2005-08-18 주식회사 엘지생활건강 Medicine comprising procyanidine as an effective agent
WO2002076381A2 (en) * 2001-03-15 2002-10-03 Proteotech, Inc. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
EP1256335A1 (en) 2001-05-10 2002-11-13 Cognis France S.A. Use of procyanidine oligomers
CN1443533A (en) * 2002-03-07 2003-09-24 程彦杰 Application of proanthcyanidin compound in preparation of alcoholism-relieving liver-protecting product
KR100531472B1 (en) * 2002-08-09 2005-11-28 주식회사 이롬 Cosmetic composition comprising extract of Rosa multiflora with antioxdative activity and preparation method of the extract
JP2006232670A (en) * 2003-05-20 2006-09-07 Ajinomoto Co Inc Medicine for nervous disorder
JP2005097273A (en) * 2003-08-19 2005-04-14 Toyo Shinyaku:Kk Athletic ability-enhancing composition
JPWO2005030200A1 (en) * 2003-09-26 2006-12-07 麒麟麦酒株式会社 Autoimmune disease treatment
CN100586431C (en) 2007-09-28 2010-02-03 天津市尖峰天然产物研究开发有限公司 Application of procyanidin B2 in preparing medicine for preventing and treating diabetes and vascular complication
TWI370736B (en) 2008-12-31 2012-08-21 Ind Tech Res Inst Pharmaceutical composition for treating hepatitis b and heath food for inhibiting hepatitis b virus
US20130123204A1 (en) * 2008-12-31 2013-05-16 Industrial Technology Research Institute Method for treating hepatitis b
CN101822372A (en) * 2009-03-05 2010-09-08 财团法人工业技术研究院 Medical compound for curing hepatitis B and health food for inhibiting hepatitis B virus
JP2012524077A (en) * 2009-04-17 2012-10-11 カルデロ セラピューティクス，インコーポレイテッド Methods and compositions for the treatment of ischemic and mitochondrial function related conditions
TWI458487B (en) 2009-12-30 2014-11-01 Ind Tech Res Inst Use of pharmaceutical compositions
JP2011178728A (en) 2010-03-02 2011-09-15 Kobe Univ Ampk activator, glut4 activator and pharmaceutical drug and food and drink using the same
ES2668785T3 (en) 2011-03-22 2018-05-22 Industrial Technology Research Institute Pharmaceutical composition to induce liver regeneration
WO2012163588A2 (en) 2011-05-27 2012-12-06 Unilever Plc Anti-ageing composition
JP2014521702A (en) * 2011-08-05 2014-08-28 カーデロ セラピューティクス インコーポレイテッド Flavonoid compounds
JP5813576B2 (en) * 2012-05-22 2015-11-17 アピオン・ジャパン有限会社 Sirtuin 1 (SIRT1) gene activator
CN102688230B (en) 2012-06-20 2014-12-03 浙江萧山医院 New applciation of procyanidine B2
CN102688501A (en) 2012-06-20 2012-09-26 浙江萧山医院 Proanthocyanidin B2 phospholipid compound, and preparation method and application thereof
AU2012394377A1 (en) * 2012-11-08 2015-09-17 Cellarouge Pty Ltd Modified polyphenols and modified polyphenol compositions

Also Published As

Publication number Publication date
US20140179774A1 (en) 2014-06-26
EP2838528A1 (en) 2015-02-25
CN104487069A (en) 2015-04-01
WO2014101366A1 (en) 2014-07-03
JP2016502532A (en) 2016-01-28
KR20150013629A (en) 2015-02-05
KR20170027860A (en) 2017-03-10
IN2014MN02382A (en) 2015-08-14
JP6305422B2 (en) 2018-04-04
EP2838528A4 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201809064QA (en) Chimeric neurotoxins
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201407900WA (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
SG11201903938XA (en) Acylated glp-1/glp-2 dual agonists
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201407200TA (en) Liquid formulation
SG11201408791TA (en) Dihydropyrimidine compounds and their application in pharmaceuticals
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201408261UA (en) Syringe
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201906958TA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201806424TA (en) Therapeutic compounds
SG11201407599SA (en) Oligonucleotide chelate complex-polypeptide compositions and methods